Investment Rating - The report assigns a "Buy" rating for Jiangsu Bank, marking its first coverage [5]. Core Insights - Jiangsu Bank is a leading city commercial bank deeply rooted in the Yangtze River Delta, with a competitive edge in return on equity (ROE) [5]. - The bank has demonstrated strong fundamentals, leading several key metrics in the industry [5]. Summary by Sections Market Performance - Closing price as of March 17, 2026, is CNY 10.91, with a yearly high of CNY 12.64 and a low of CNY 9.08 [3]. - Total market capitalization is CNY 200.21 billion, with a circulating market value of CNY 200.21 billion [3]. Business Overview - Jiangsu Bank has a significant presence in Jiangsu, with a loan market share of 7.23% as of mid-2025, leading among city commercial banks [6]. - The bank's total assets reached CNY 4.9 trillion by Q3 2025, marking a year-on-year growth of 27.8% [16]. - The bank's retail loans stood at CNY 686.5 billion, accounting for 27.8% of total loans as of Q3 2025 [6]. Financial Performance - Jiangsu Bank's operating income for Q3 2025 was CNY 672 billion, reflecting a year-on-year growth of 7.8% [20]. - The net profit attributable to shareholders for Q3 2025 was CNY 306 billion, with an annual growth of 8.3% [20]. - The bank's net interest margin for 2024 was 1.86%, higher than the A-share listed bank average of 1.51% [6]. Asset Quality - The non-performing loan (NPL) ratio was 0.84% as of Q3 2025, significantly lower than the A-share listed bank average of 1.21% [9]. - The bank's provision coverage ratio was 323% as of Q3 2025, indicating strong asset quality management [9]. Growth Prospects - Jiangsu Bank's net profit is projected to grow to CNY 348 billion in 2025, with a year-on-year growth rate of 9.2% [8]. - The bank's return on equity (ROE) is expected to be 13.6% in 2024, surpassing the A-share listed bank average of 10.1% [8]. Competitive Position - Jiangsu Bank has a diversified business model, focusing on corporate, retail, and middle-income businesses, which drives its growth [55]. - The bank's corporate loans are primarily directed towards manufacturing and infrastructure, with a combined loan balance of CNY 1.19 trillion, accounting for 48.9% of total loans as of mid-2025 [6][58].

Investment Rating - The report maintains a "Recommendation" rating for the company [1] Core Insights - The company has achieved significant breakthroughs in eVTOL logistics, completing successful test flights and establishing operational capabilities in the low-altitude economy [2] - The company is expanding its diversified low-altitude application scenarios, with notable developments in weather modification and the establishment of a digital tower in Shenzhen [2] - The company’s financial performance shows steady growth, with total revenue for 2025 reaching 2.235 billion, a year-on-year increase of 3.3%, and a net profit of 309 million, up 1.8% year-on-year [7] - The company is positioned to benefit from the low-altitude economy, which has been recognized as a new pillar industry by the government [8] Financial Summary - Total revenue projections for 2026-2028 are 2.439 billion, 2.673 billion, and 2.925 billion respectively, with corresponding growth rates of 9.1%, 9.6%, and 9.4% [3] - Net profit projections for the same period are 368 million, 412 million, and 470 million, with growth rates of 19.1%, 12.1%, and 14.2% respectively [3] - The company’s earnings per share (EPS) are forecasted to be 0.47, 0.53, and 0.61 yuan for 2026, 2027, and 2028 respectively [8] Company Data - The total share capital is 77,577.01 million shares, with a total market value of 157.33 billion [4] - The company has an asset-liability ratio of 28.40% and a net asset value per share of 7.05 yuan [4]

证券研究报告·北交所公司点评报告·通用设备 | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 310.26 | 361.85 | 445.50 | 530.40 | 630.40 | | 同比 | (9.06) | 16.63 | 23.12 | 19.06 | 18.85 | | 归母净利润（百万元） | 13.07 | 42.13 | 53.89 | 64.58 | 78.08 | | 同比 | (70.99) | 222.30 | 27.93 | 19.83 | 20.89 | | EPS-最新摊薄（元/股） | 0.15 | 0.49 | 0.63 | 0.76 | 0.92 | | P/E（现价&最新摊薄） | 143.42 | 44.50 | 34.79 | 29.03 | 24.01 | [Table_Tag] [Table_Summary] 投资要点 2026 年 03 月 17 日 证券分析师 朱洁羽 执业证书 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][5] Core Views - The company is expected to experience significant revenue growth driven by AI, communication, and automotive sectors, with a notable increase in PCB business [3][8] - The company has achieved breakthroughs in packaging substrate technology and accelerated customer onboarding, contributing to high growth in this segment [3][8] Financial Summary - The company’s projected revenue for 2025 is RMB 23.65 billion, representing a year-over-year growth of 32% [7][8] - The estimated EPS for 2026 is RMB 8.54, with a projected PE ratio of 29.8 [5][7] - The EBITDA for 2025 is expected to reach RMB 4.84 billion, with a growth rate of 47.1% [7][11] Business Segments - PCB business revenue is projected to be RMB 14.36 billion in 2025, with a growth rate of 37% [8] - The packaging substrate business is expected to generate RMB 4.15 billion in revenue for 2025, with a growth rate of 31% [8] Market Position - The company is anticipated to rank fourth among global PCB manufacturers by revenue in 2025 [8] - The global PCB market is projected to grow from USD 85.2 billion to USD 123.3 billion from 2025 to 2030, with a CAGR of approximately 8% [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved a revenue of 362 million yuan in 2025, representing a year-on-year growth of 16.63%, and a net profit attributable to shareholders of 42.13 million yuan, which is a significant increase of 222.30% year-on-year [6] - The company is focusing on expanding its high-end product matrix through new product launches in chromatography and mass spectrometry, which is expected to accelerate business growth [5] - The overall gross margin improved to 65.04%, with a notable increase in the chromatography series gross margin by 4.12 percentage points to 58.55% [6] - The company plans to implement a simplified procedure for a targeted stock issuance to raise funds, which could facilitate efficient financing of less than 100 million yuan [6] Financial Performance Summary - In 2025, the company reported a net cash flow from operating activities of 50.52 million yuan, up 80.52% year-on-year [6] - The company’s four core scientific instrument series showed robust growth, with the sample pretreatment series leading with a revenue of 70.86 million yuan, a year-on-year increase of 23.27% [6] - The domestic market revenue reached 284 million yuan, growing by 18.40% year-on-year, while overseas revenue was 77.79 million yuan, up 10.59% [6] - The company’s earnings per share (EPS) for 2025 is projected at 0.49 yuan, with a forecasted PE ratio of 45.55 [8] Future Outlook - The company is expected to continue its growth trajectory with projected net profits of 60 million yuan in 2026, 80 million yuan in 2027, and 102 million yuan in 2028, corresponding to a PE ratio of 32, 24, and 19 respectively [8] - The company is actively expanding into strategic emerging sectors such as biomanufacturing, nuclear industry, new materials, and new energy, with significant customer acquisition success [6] - The company is also focusing on R&D and product breakthroughs across its major product lines, including the development of an automated nitrogen analyzer and a new generation microwave digestion instrument [7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a total revenue of 154.73 billion yuan for 2025, a decrease of 13.53% year-on-year, with a net profit attributable to shareholders of 1.02 billion yuan, down 74.65% year-on-year [8] - The decline in revenue and profit was attributed to a decrease in the scale of revenue recognition and gross margin, along with reduced investment income [8] - The company focused on core cities, achieving a sales area of 7.16 million square meters, a decrease of 23.5% year-on-year, but the average sales price increased by 16.8% to 27,000 yuan per square meter [8] - Investment in core cities increased, with total land acquisition area of 4.4 million square meters and total land cost of 93.8 billion yuan, a 93% increase year-on-year [8] - The company maintained a healthy financial position with a net cash flow from operating activities of 9.693 billion yuan and a cash balance of 86.127 billion yuan at the end of 2025 [8] - The forecast for net profit attributable to shareholders for 2026-2028 is 1.31 billion, 1.63 billion, and 2.00 billion yuan, respectively, with corresponding PE ratios of 66.3x, 53.3x, and 43.4x [8] Financial Performance Summary - Revenue forecast for 2024A is 178.95 billion yuan, with a growth rate of 2.3%, followed by 154.73 billion yuan in 2025A, a decline of 13.5% [7] - Net profit for 2024A is projected at 4.04 billion yuan, with a significant drop to 1.02 billion yuan in 2025A, reflecting a net profit growth rate of -74.6% [7] - The company's gross margin for 2025 was 15.33%, a slight decrease of 0.25 percentage points year-on-year [8] - The company’s return on equity (ROE) is expected to improve from 1.0% in 2025 to 2.0% by 2028 [7]

Investment Rating - The report maintains a "Recommendation" rating for CITIC Heli (000099) [1] Core Insights - The company has achieved significant breakthroughs in eVTOL logistics scenarios, completing successful test flights and establishing operational capabilities in the low-altitude economy [2] - The company is expanding its diversified low-altitude application scenarios, with notable developments in weather modification and the establishment of a digital tower in Shenzhen [2] - The financial performance for 2025 shows steady growth, with total revenue reaching 2.235 billion yuan, a year-on-year increase of 3.3%, and a net profit of 309 million yuan, up 1.8% year-on-year [7] Financial Summary - **Revenue Forecasts**: - 2025: 2,235 million yuan - 2026: 2,439 million yuan (9.1% growth) - 2027: 2,673 million yuan (9.6% growth) - 2028: 2,925 million yuan (9.4% growth) [3] - **Net Profit Forecasts**: - 2025: 309 million yuan - 2026: 368 million yuan (19.1% growth) - 2027: 412 million yuan (12.1% growth) - 2028: 470 million yuan (14.2% growth) [3] - **Earnings Per Share (EPS)**: - 2025: 0.40 yuan - 2026: 0.47 yuan - 2027: 0.53 yuan - 2028: 0.61 yuan [3] - **Valuation Ratios**: - Price-to-Earnings (P/E) ratio for 2026: 43 times - Price-to-Book (P/B) ratio for 2026: 2.7 times [3] Company Data - **Total Shares**: 77,577.01 million shares - **Market Capitalization**: 157.33 billion yuan - **Debt-to-Asset Ratio**: 28.40% [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is focusing on solidifying its premium content supply and commercializing AI products [1] - In 2025, the company achieved a total revenue of 1.702 billion yuan, with a year-on-year growth of 0.87%, and a net profit attributable to shareholders of 130 million yuan, reflecting a year-on-year increase of 9.63% [4][5] - The company is positioned as a leader in the retail book market, with significant sales in various categories, including strong performance in IP books related to film and gaming [5][6] Revenue and Profitability - The company's main revenue streams in 2025 were from book publishing (1.29 billion yuan), digital services (236 million yuan), and urban cultural space operations (344 million yuan), with respective year-on-year growth rates of -1.35%, +6.02%, and +10.2% [5] - The overall gross margin for the three main business segments was 39.74%, 29.42%, and 34.35% respectively [5] - The company forecasts revenues of 1.756 billion yuan, 1.817 billion yuan, and 1.899 billion yuan for 2026, 2027, and 2028 respectively, with corresponding EPS of 0.87, 1.03, and 1.20 yuan [9][11] Strategic Initiatives - The company is actively building a "knowledge community" and enhancing its product capabilities through its KuaFu AI platform, which significantly improves publishing efficiency [6][7] - The company aims to commercialize AI technology outcomes and explore new product offerings, including AI-powered publishing platforms and intelligent book agents [9]

Investment Rating - The report gives the company an "Accumulate" rating for the first time, with expected earnings per share of 0.23 yuan and 0.34 yuan for 2025 and 2026, respectively, corresponding to valuations of 174 times and 119 times [5]. Core Insights - The company is a leading domestic player in cardiovascular precision intervention, focusing on innovative medical devices for cardiovascular disease diagnosis and treatment [6][13]. - The precision PCI market in China is expected to grow rapidly, with the market size projected to increase from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, reflecting a compound annual growth rate (CAGR) of approximately 21.1% [6][43]. - The company has established a comprehensive product pipeline and solution for precision intervention, leveraging its four core technology platforms to maintain a competitive edge in the market [6][26]. Summary by Sections Company Overview - The company specializes in the research, development, production, and sales of innovative medical devices for cardiovascular diseases, with core products including the IVUS diagnostic system and FFR measurement system, both of which are the first domestically approved products in their respective categories [13][22]. - The company has achieved significant recognition and awards, including being designated as a "National Specialized and New 'Little Giant' Enterprise" and a provincial manufacturing champion [13][14]. Business Performance - The company has experienced rapid revenue growth, with revenues increasing from 0.02 billion yuan in 2020 to 3.12 billion yuan in 2024, representing a CAGR of 270.81% [26][27]. - The core product, the IVUS diagnostic system, has become a major revenue source, accounting for over 60% of the company's main business income in recent years [29]. Market Trends - The PCI market in China is expected to see a significant increase in surgical volume, projected to grow from 1.906 million procedures in 2024 to 4.298 million by 2030, with a CAGR of approximately 14.5% [40][41]. - The penetration rate of precision PCI technologies like FFR and IVUS is expected to rise, driven by increasing awareness and demand for precise diagnosis and treatment in cardiovascular care [51][47].

丨证券研究报告丨 [Table_scodeMsg1] 公司研究丨点评报告丨中航高科（600862.SH） [Table_Title] 需求短期波动，低空民航市场拓展可期 报告要点 [Table_Summary] 公司发布 2025 年年报，2025A 实现营收 50.08 亿，yoy-1.27%；归母净利润 10.31 亿，yoy- 10.57%；扣非归母净利润 10.22 亿，yoy-10.07%。2025Q4 实现营收 12.46 亿，yoy-0.38%， qoq+22.91%；归母净利润 2.25 亿，yoy-6.72%，qoq+11.57%；扣非归母净利润 2.24 亿，yoy- 6.25%，qoq+14.69%。 分析师及联系人 [Table_Author] 王贺嘉 张晨晨 SAC：S0490520110004 SAC：S0490524080007 SFC：BUX462 $${\mathrm{iii}}\{8\}{\mathrm{iii}}\{8\}{\mathrm{iii}}\{8\}{\mathrm{iii}}\{8\}{\mathrm{iii}}\{8\}{\mathrm{iii}}\{8\} ...